Cargando…

Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients

BACKGROUND AND AIM: Sarcopenia has received much attention as a poor prognostic factor in various fields, and has also been reported to worsen prognosis in patients with hepatocellular carcinoma (HCC) treated with sorafenib or lenvatinib (LEN). Atezolizumab/bevacizumab (ATZ/BEV) is recommended as fi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toshida, Katsuya, Itoh, Shinji, Tomiyama, Takahiro, Morinaga, Akinari, Kosai, Yukiko, Tomino, Takahiro, Kurihara, Takeshi, Nagao, Yoshihiro, Morita, Kazutoyo, Harada, Noboru, Yoshizumi, Tomoharu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Publishing Asia Pty Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260215/ https://www.ncbi.nlm.nih.gov/pubmed/35822124 http://dx.doi.org/10.1002/jgh3.12777

Ejemplares similares

Prevention of bile duct injury using indocyanine green fluorescence in laparoscopic liver cyst fenestration for giant liver cyst: a case report
por: Shimagaki, Tomonari, et al.
Publicado: (2022)

Cancer‐associated fibroblasts promote tumor cell growth via miR‐493‐5p in intrahepatic cholangiocarcinoma
por: Toshida, Katsuya, et al.
Publicado: (2022)

Caution for living donor liver transplantation with congenital portosystemic shunt: a case report
por: Nagao, Yoshihiro, et al.
Publicado: (2022)

Donor Skeletal Muscle Quality Affects Graft Mortality After Living Donor Liver Transplantation- A Single Center, Retrospective Study
por: Tomiyama, Takahiro, et al.
Publicado: (2022)

Myeloid-derived suppressor cell infiltration is associated with a poor prognosis in patients with hepatocellular carcinoma
por: Tomiyama, Takahiro, et al.
Publicado: (2022)

Association between Sarcopenia and Omega-3 Polyunsaturated Fatty Acid in Patients with Hepatocellular Carcinoma
por: Itoh, Shinji, et al.
Publicado: (2022)

Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor‐4 inhibition in hepatocellular carcinoma
por: Iseda, Norifumi, et al.
Publicado: (2022)

Clinical effects of the use of the indocyanine green fluorescence imaging technique in laparoscopic partial liver resection
por: Itoh, Shinji, et al.
Publicado: (2022)

Curative surgery for multiple hepatocellular carcinomas after lenvatinib plus transarterial chemoembolization: a case report
por: Shiraishi, Jin, et al.
Publicado: (2023)

A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients
por: Tomiyama, Takahiro, et al.
Publicado: (2023)

Acute death caused by invasive aspergillosis after living-donor liver transplantation despite good graft function: a case report
por: Tomiyama, Takahiro, et al.
Publicado: (2021)

Impact and risk factors for skeletal muscle mass loss after hepatic resection in patients with hepatocellular carcinoma
por: Itoh, Shinji, et al.
Publicado: (2021)

Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
por: Yano, Shigeki, et al.
Publicado: (2021)

CMTM6 Stabilizes PD‐L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma
por: Yugawa, Kyohei, et al.
Publicado: (2020)

Hemophagocytic syndrome after living donor liver transplantation: a case report with a review of the literature
por: Iseda, Norifumi, et al.
Publicado: (2018)

Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Niizeki, Takashi, et al.
Publicado: (2022)

ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma
por: Iseda, Norifumi, et al.
Publicado: (2020)

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Yano, Shigeki, et al.
Publicado: (2023)

Impact of Nuclear Factor Erythroid 2–Related Factor 2 in Hepatocellular Carcinoma: Cancer Metabolism and Immune Status
por: Iseda, Norifumi, et al.
Publicado: (2021)

Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series
por: Ichimura, Takenori, et al.
Publicado: (2023)

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
por: Gong, Hongyu, et al.
Publicado: (2023)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma
por: Kosaka, Yumi, et al.
Publicado: (2022)

Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma
por: Su, Chung‐Wei, et al.
Publicado: (2022)

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
por: Zhao, Chenghao, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma
por: Itoh, Shinji, et al.
Publicado: (2022)

Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
por: Kim, Beom Kyung, et al.
Publicado: (2022)

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
por: Rimini, M., et al.
Publicado: (2022)

Atezolizumab plus bevacizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis
por: Giri, Suprabhat, et al.
Publicado: (2023)

DsRNA Sequencing for RNA Virus Surveillance Using Human Clinical Samples
por: Izumi, Takuma, et al.
Publicado: (2021)

Up‐regulated LRRN2 expression as a marker for graft quality in living donor liver transplantation
por: Tomiyama, Takahiro, et al.
Publicado: (2022)

Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis
por: Du, Sihao, et al.
Publicado: (2023)

Predictor of outcome after living donor liver transplantation for patients with hepatocellular carcinoma beyond the Japan criteria
por: Yonemura, Yusuke, et al.
Publicado: (2020)

Impact of JMJD6 on intrahepatic cholangiocarcinoma
por: Kosai-Fujimoto, Yukiko, et al.
Publicado: (2022)

Which is better to use “body weight” or “standard liver weight”, for predicting small‐for‐size graft syndrome after living donor liver transplantation?
por: Toshima, Takeo, et al.
Publicado: (2020)

Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy
por: Oura, Kyoko, et al.
Publicado: (2023)

Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Hepatocellular carcinoma with gastric adenocarcinoma treated with atezolizumab and bevacizumab
por: Suga, Takayoshi, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma
por: Brackenier, Cedric, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_86fqsras2h1rnko3ij3kksqkpb